Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial.

MLA

Zhang, Dong-Sheng, et al. “Surufatinib Combined with TAS-102 as a Late-Line Therapy in Patients with Metastatic Pancreatic Cancer (MPDAC): Updated Results of a Single-Arm, Phase II Trial.” Journal of Clinical Oncology, vol. 43, Feb. 2025, p. 739. EBSCOhost, https://doi.org/10.1200/JCO.2025.43.4_suppl.739.

APA

Zhang, D.-S., Lu, Y.-X., Liu, F.-R., Bai, B., Zhang, Y., Wang, Z., Liu, Y., Chen, J.-W., Li, Y.-H., Wang, F.-H., Guo, G. F., Wang, F., & Xu, R.-H. (2025). Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial. Journal of Clinical Oncology, 43, 739. https://doi.org/10.1200/JCO.2025.43.4_suppl.739

Chicago

Zhang, Dong-Sheng, Yun-Xin Lu, Fu-Rong Liu, Bing Bai, Yang Zhang, Zhiqiang Wang, Yu Liu, et al. 2025. “Surufatinib Combined with TAS-102 as a Late-Line Therapy in Patients with Metastatic Pancreatic Cancer (MPDAC): Updated Results of a Single-Arm, Phase II Trial.” Journal of Clinical Oncology 43 (February): 739. doi:10.1200/JCO.2025.43.4_suppl.739.